France Trades €100 Million in Price Relief for an Annual Review of Older Drugs
France has moved the reimbursement threat from price to presence: a competitor’s launch can now put an incumbent under review.
France has moved the reimbursement threat from price to presence: a competitor’s launch can now put an incumbent under review.
Latvia is buying access with manufacturers’ money, inside a reimbursement budget NVD already expects to overrun.
Up to $7.8 billion for an mRNA engager with efficacy data from three patients, 32 days after Novartis halted its CAR-T.
Sobi is moving its FCS franchise to a less frequent, better-tolerated drug, on broader NICE terms than the one it replaces.
The numbers are small, but the rule is unusual: New Zealand funds by tumour type and protocol rather than product by product.
One reimbursement decision moved a second-line PD-1 into first line across three common cancers, inside biomarker limits.
Sanofi is paying to keep Dupixent’s next generation in the partnership, and the deal also closes a lawsuit between them.
The premium headline is real, but part of the cost has moved from the monthly bill to the point of care.
The default gets shorter, and the route back to the maximum runs through comparative trials and filing early in Europe.
The injection keeps hospital claims paid for two months. It does not change the arithmetic that created the gap.